Sharp Services has announced a $20m investment into its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie (PA, US).
The announcement follows recent market reports predicting that the autoinjector market is projected to reach $20.6bn globally by 2030, with a CAGR of 15.1%.
This is due in part to convenience and usability for both patients and healthcare providers.
The upgraded facility in Macungie will boast two autoinjector assembly lines to support both clinical and commercial needs.
Investments include a low-speed semi-manual, two-devices-per-minute line to support the assembly of custom and non-custom pens and autoinjectors.
The second line will offer mid-speed assembly of 50–70 devices per minute, featuring inline labelling and cartoning.
It will support both Ypsomed’s YpsoMate and SHL Medical’s Molly autoinjectors.
Jeff Benedict, Chief Commercial Officer at Sharp, commented: “Pharma organisations are increasingly choosing injectables in advanced delivery systems that ensure reliable and safe drug administration, especially in critical or emergency scenarios."
"The rapid rise in demand for obesity management products, coupled with the market requirement for more sustainable solutions, has fuelled innovation and unlocked new possibilities in this space.”
The autoinjectors and pens assembled, labelled and packaged at Sharp will be used for a wide range of emergency, chronic and speciality conditions.
The new production lines in Macungie, which will support the specific requirements of these devices and therapies, are expected to be fully operational in the first half of 2027.
Benedict continued: “Following the successful implementation of our assembly capabilities at our Hamont-Achel facility in Belgium, our new production lines in the US will position Sharp to support the global market."
"Sharp’s expertise in autoinjector packaging, combined with our experience in the global market, makes this an exciting opportunity for our existing and new clients.”
With a network of nine GMP facilities across the US, UK and Europe, Sharp has a deep knowledge and breadth of expertise to support clients with integrated sterile manufacturing, clinical trial services and commercial packaging solutions.